肾康注射液联合前列地尔注射液对糖尿病肾病患者尿单核细胞趋化蛋白-1的影响  

Influence of Shenkang Injection Combined with Alprostadil Injection on Monocyte Chemoattractant Protein-1 in Diabetic Nephropathy

作　　者：柯宗萍[1] 李敏[1] 胡海霞[1] 

机构地区：[1]十堰市太和医院湖北医药学院附属医院,湖北十堰442000

出　　处：《河南中医》2017年第3期469-471,共3页Henan Traditional Chinese Medicine

基　　金：十堰太和医院院级基金项目(编号:2012HLXM04)

摘　　要：目的:观察肾康注射液联合前列地尔注射液对糖尿病肾病(diabetic nephropathy,DN)患者尿单核细胞趋化蛋白-1的影响。方法:选取2013年7月—2014年12月本院住院及门诊治疗的DN患者80例,随机分为治疗组和对照组,每组40例。两组患者均给予常规降血糖、降血压、降血脂治疗,对照组给予肾康注射液治疗,治疗组在对照组治疗的基础上加用前列地尔注射液治疗。结果:治疗组治疗后尿MCP-1水平优于对照组(P<0.05);两组治疗后BUN、Cr、UAER、β2-MG均较治疗前显著下降(P<0.05),但两组间BUN、Cr比较无显著性差异(P>0.05),治疗组治疗后UAER、β2-MG优于对照组(P<0.05)。结论:肾康注射液联合前列地尔注射液能够有效降低早期DN患者尿MCP-1水平,抑制炎症反应,降低尿蛋白,改善肾功能。Objective： To observe the clinical effects of Shenkang Injection combined with Alprostadil Injection on Monocyte Chemoattractant Protein-1（ MCP-1） in diabetic nephropathy（ DN）. Methods： Totally 80 patients with DN treated in this hospital between July 2013 and December 2014 were randomized into treatment group and control group,40 cases in each group. Both group were given conventional sugar-reducing,pressure-reducing and lipid-reducing treatment. Control group were given Shenkang Injection while treatment group were added with Alprostadil Injection on the basis of control group. Results： The level of MCP-1 in treatment group was superior to that in control group（ P 〈 0. 05）. The levels of BUN,Cr,UAER andβ2-MG in both groups declined greatly in both groups（ P 〈 0. 05）. The difference of BUN and Cr between the two groups had no significant difference（ P 〉0. 05）. The levels of UAER andβ2-MG in treatment group were superior to those in control group（ P 〈 0. 05）. Conclusion： Shenkang Injection combined with Alprostadil Injection can effectively reduce the MCP-1 level of patients with DN,which can inhibit the inflammatory reaction,reduce the urine protein and improve the kidney function.

关 键 词：糖尿病肾病 前列地尔 肾康注射液 尿单核细胞趋化蛋白-1 

分 类 号：R259.872[医药卫生—中西医结合]